- Home
- STBA vs AUPH Comparison
STBA vs AUPH Comparison
Compare STBA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STBA | AUPH |
|---|---|---|
| Founded | 1902 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | STBA | AUPH |
|---|---|---|
| Price | $43.60 | $14.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $42.20 | $17.25 |
| AVG Volume (30 Days) | 191.1K | ★ 968.0K |
| Earning Date | 01-22-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | ★ 2.27 | N/A |
| EPS | ★ 3.49 | 0.55 |
| Revenue | ★ $394,697,000.00 | $265,808,000.00 |
| Revenue This Year | $9.61 | $21.76 |
| Revenue Next Year | $4.87 | $16.45 |
| P/E Ratio | ★ $12.60 | $26.50 |
| Revenue Growth | 2.85 | ★ 20.62 |
| 52 Week Low | $30.84 | $6.55 |
| 52 Week High | $44.27 | $16.54 |
Technical Indicators
Market Signals| Indicator | STBA | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 62.67 | 40.98 |
| Support Level | $41.46 | $14.35 |
| Resistance Level | $42.51 | $15.47 |
| Average True Range (ATR) | 1.36 | 0.46 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 79.87 | 13.97 |
Price Performance
Historical ComparisonAbout STBA S&T Bancorp Inc.
S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. It operates only in one segment which is Community Banking. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.